AstraZeneca Under Chinese Compliance Probe; Lung Cancer Drug Trial Results Disappoint

Investigation targets data privacy breaches and unlicensed medication imports; latest trial shows limited efficacy but CEO defends overall portfolio strength.

AstraZeneca faces a compliance investigation in China involving the detention of current and former employees.
The probe focuses on potential breaches of data privacy laws and the importation of unlicensed cancer medications.
The company's TROPION-Lung01 Phase 3 trial results for the lung cancer drug datopotamab deruxtecan showed a clinically meaningful trend but did not reach statistical significance for overall survival.
CEO Pascal Soriot emphasized the strength of AstraZeneca's drug portfolio despite the market's reaction to the trial results.
AstraZeneca's shares dropped over 5% following the announcement of the trial results.